Download PDF
CC BY-NC-ND 4.0 · Indian J Med Paediatr Oncol 2005; 26(02): 5-17
DOI: 10.1055/s-0041-1733114
Original Article

Therapy with Imatinib Mesylate for Chronic Myeloid Leukemia

BRIJESH ARORA
Department ofMedicla Oncology, Tata Memorial Hospital, Mumbai 400012, India
,
LALIT KUMAR
Department of Medicla Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
,
MAMTA KUMARI
Department of Medicla Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
,
ATUL SHARMA
Department of Medicla Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
,
JYOTI WADHAWA
Department of Medicla Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
,
V KOCHUPILLAI
Department of Medicla Oncology, Institute Rotary Cancer Hospital, All India Institute of Medical Sciences, New Delhi 110029, India
› Author Affiliations
› Further Information
Also available at
  PDF Download Permissions and Reprints


Publication History

Article published online:
28 March 2022

© 2005. Indian Society of Medical and Paediatric Oncology. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/.)

Thieme Medical and Scientific Publishers Pvt. Ltd.
A-12, 2nd Floor, Sector 2, Noida-201301 UP, India

 

  • References

  • 1 Sawyers CL. Chronic myeloid leukemia. NEJM 1999;340:1330-1340.
  • 2 Baccarani M. Non-transplant treatment options for patients with newly diagnosed chronic myeloid leukemia. In Hematology 2001, American Society of Hematology; Education Program Book , Ed. Schechter GP, Broudy VC, and Williams ME. Pp98-103.
  • 3 Goldman JM and Melo JV Targeting the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEJM 2001;344:1084-86.
  • 4 Savage DG and Antman KH. Drug therapy : Imatinib mesylate - A new oral targeted therapy NEJM 2002;346:683-693
  • 5 Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. NEJM2001;344:1031-7.
  • 6 Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. NEJM 2001;344:1038-42.
  • 7 O’Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low dose cytarabine for newly diagnosed chronic phase chronic myeloid leukemia. NEJM2003;348:994-1004.
  • 8 Kumar L, Gangadharan VP, Raghunadharao D, Saikia T Shah S, Malhotra H, Bapsy PP, Singh K, Rao R. Study on the safety and efficacy of an indigenous recombinant interferon alpha-2b (Shanferon) in chronic myelogenous leukemia (CML) patients : Results of a multicentric trial from India. Nat Med Jn India 2005 (in press).
  • 9 Lokeshwar N, Kumar, L and Kumari M. Severe bone marrow aplasia following imatinib mesylate in a patient with chronic myelogenous leukemia. Leuk & Lymphoma 2005 (in press).
  • 10 Gambacorti -Passerini CB, Gunby RH, Piazza R, et al. Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukemias. Lancet Oncology 2003;4:75-85.
  • 11 Kumar L, Kumari M, Kumar S, and Kochupillai V Chronic myelogenous leukemia (CML). Ind J Hematol & Trans Medicine 2003;21:21-26.
  • 12 Kantarjian H, Talpaz M, O’Brien S, et al. Prediction of initial cytogenetic response for subsequent major and complete cytogenetic response to imatinib mesylate therapy in patients with Philadelphia chromosome - positive chronic myelogenous leukemia. Cancer 2003;97:2225-8.
  • 13 Kantarjian HM, O’brien S, Cortes J, et al. Imatinib mesylate therapy improves survival in patients with newly diagnosed Philadelphia chromosome - positive chronic myelogenous leukemia in the chronic phase : comparison with historic data. Cancer 2003;98:2636-42.
  • 14 Peggs K andMackinnon S. Imatinib mesylate - The new gold standard for treatment of chronic myeloid leukemia. NEJM2003;348:1048-1050
  • 15 Goldman JM. Chronic myeloid leukemia - still a few questions. Exp Hematol 2004;32:2-10.
  • 16 Braziel RM, Launder TM, Druker BJ, et al. Hematologic and cytogenetic findings in imatinib mesylate - treated chronic myelogenous leukemia patients : 14 months experience. Blood 2002;100:435-441.
  • 17 Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. NEJM 2002;346:645-652.
  • 18 Olavarria E, Craddock C, Dazzi F, et al. Imatinib mesylate (STI571) in the treatment of relapse of chronic myeloid leukemia after allogeneic stem cell transplantation. Blood 2002;99:3861-3862.
  • 19 Tsao AS, Kantarjian H, Cortes J, O’Brien S, Talpaz M. Imatinib mesylate causes hypopigmentation in the skin. Cancer 2003;98:2483-7.
  • 20 Drummond A, Micallef -Eynaud P, Douglas WS, et al. A spectrum of skin reactions caused by the tyrosine kinase inhibitor imatinib mesylate (STI-571,Glivec). Brit J Haematol 2003120:911-3.
  • 21 Valeyrie L, Bastuji-Garin S, Revuz J, et al. Adverse cutaneous reactions to imatinib (STI-571) in Philadelphia chromosome- positive leukemias : a prospective study of 54 patients. J Am Acad Dermatol 2003;48:201-6.
  • 22 Van Oosterom AT, Judson I, Verweij J, et al. Safety and efficacy of Imatinib (STI 571) in metastatic gastrointestinal stromal tumours : a phase I study. Lancet 2001; 358:1421-3.
  • 23 Gambacorti-Passerini C, Tornaghi L, Cavagnini F, Rossi P, Pecori-Geraldi F, Mariana L, et al. Gynaecomastia in men with chronic myeloid leukemia after imatinib. Lancet 2003;361:1954-56.
  • 24 Ohyashiki K, Kuriyama Y, Nakajima A, et al. Imatinib mesylate - induced hepato-toxicity in chronic myeloid leukemia demonstrated focal necrosis resembling acute viral hepatitis. Leukemia 2003;16:160-1.
  • 25 Dann EJ, Fineman R, Rowe JM. Tumour lysis syndrome after STI-571 in Philadelphia chromosome positive acute lymphoblastic leukemia. J. Clin. Oncol 2002; 20(1)354-5
  • 26 Deininger MWN, O’Brien SG, Ford JM, and Druker BJ. Practical management of patients with chronic myeloid leukemia receiving imatinib. J Clin Oncol 2003;21:1637- 1647.
  • 27 Sneed TB, Kantarjian HM, Talpaz M, et al. the significance of myelosuppression during therapy with imatinib mesylate in patients with chronic myelogenous leukemia in chronic phase. Cancer 2004;100:116-21.
  • 28 Marin D, Marktell S, Foot N, Bua M, Olavarria E, Goldman JM, Apperley JF. G-CSFreverses cytopenia and may permit cytogenetic responses in patients with chronic myeloid leukemia treated with imatinib mesylate. Haematologica. 2003;88:227-229
  • 29 Mattiuzzi GN, Cortes JE, Talpaz M, et al. Development of varicella-zoster virus infection in patients with chronic myelogenous leukemia treated with imatinib mesylate. Clin Cancer Res 2003;9:976-80.
  • 30 Talpaz M, Kantarjian H, Kurzrock R, Gutterman JU. Bone Marrow hypoplasia and aplasia complicating interferon therapy for chronic myelogenous leukemia. Cancer. 1992;68:410-412.
  • 31 Mauro MJ O’Dwyer ME, Kurilik G, et al. Risk factors for myelosupression in chronic phase CML patients treated with imatinib mesylate. Blood. 2001;98 (Suppl 1):139a.
  • 32 Hasserjian RP, Boecklin F Parker S, et al. STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002;117:360- 367.
  • 33 Hasserjian RP, Boecklin F Parker S, et al. STI571 (imatinib mesylate) reduces bone marrow cellularity and normalizes morphologic features irrespective of cytogenetic response. Am J Clin Pathol 2002;117:360- 367.
  • 34 Wolff NC, Richardson JA, Egorin M, Ilaria RL Jr. The CNS is a sanctuary for leukemic cells in mice receiving imatinib mesylate for BCR/ABL- induced leukemia. Blood 2003;101:5010-3.
  • 35 Bornhauser M, Jenke A, Freiberg-Richter J et al. CNS blast crisis of chronic myelogenous leukemia in a patient with a major cytogenetic response in bone marrow associated with low levels of imatinib mesylate and its N-desmethylated metabolite in cerebral spinal fluid. Ann Hematol 2003.